journal
https://read.qxmd.com/read/38279671/higher-orexin-a-levels-are-associated-with-treatment-response-to-clozapine-in-patients-with-schizophrenia-a-cross-sectional-study
#21
JOURNAL ARTICLE
Po-Yu Chen, Chih-Chiang Chiu, Chin-Kuo Chang, Mong-Liang Lu, Cho-Yin Huang, Chun-Hsin Chen, Ming-Chyi Huang
BACKGROUND: Clozapine is the primary antipsychotic (APD) for treatment-resistant schizophrenia (TRS). However, only 40% of patients with TRS respond to clozapine, constituting a subgroup of clozapine-resistant patients. Recently, the neuropeptide orexin-A was shown to be involved in the pathophysiology of schizophrenia. This study evaluated the association of orexin-A levels with the clozapine response in patients with TRS. METHODS: We recruited 199 patients with schizophrenia, including 37 APD-free and 162 clozapine-treated patients...
January 27, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38279662/mdma-enhances-positive-affective-responses-to-social-feedback
#22
JOURNAL ARTICLE
Anya K Bershad, David T Hsu, Harriet de Wit
BACKGROUND: The prosocial compound ± 3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has shown promise as an adjunct to psychotherapy in the treatment of post-traumatic stress disorder. MDMA increases positive responses to social images, and it has been suggested that the ability of MDMA to positively bias social perception may underlie its therapeutic efficacy as a psychotherapy adjunct. However, the effect of the compound on affective responses to positive or negative social feedback has not been tested...
January 27, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38279659/amphetamine-use-disorder-is-associated-with-striatum-hypoactivation-during-anticipation-of-loss-and-reward
#23
JOURNAL ARTICLE
April C May, Kaiping Burrows, Rayus Kuplicki, Martin P Paulus, Jennifer L Stewart
BACKGROUND: Dysregulated ventral striatum function has been proposed as one important process occurring in individuals with substance use disorder. This study investigates the role of altered reward and loss processing, which is an important component of impaired decision-making, impulsivity, and vulnerability to relapse in individuals with amphetamine use disorder (AMP). AIMS: To determine whether AMP is associated with blunted striatum, prefrontal cortex, and insula signals during win and loss anticipation...
January 27, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38214314/the-impact-of-cannabidiol-placebo-on-responses-to-an-acute-stressor-a-replication-and-proof-of-concept-study
#24
JOURNAL ARTICLE
Radostina M Zhekova, Robin N Perry, Toni C Spinella, Kayley Dockrill, Sherry H Stewart, Sean P Barrett
BACKGROUND: Our group has previously reported that cannabidiol (CBD) expectancy alone blunts markers of stress, particularly during anticipation, but it is not clear the extent to which such findings were specific to the methods utilized. AIMS: To examine CBD-related placebo effects on stress reactivity and anticipation and to validate a protocol to be used in a neuroimaging study. METHODS: Forty-eight healthy adults (24 female) were randomly assigned to be informed that they ingested a CBD-containing oil or a CBD-free oil despite receiving the same oil (CBD-free)...
January 12, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38214279/microdosing-psychedelics-and-the-risk-of-cardiac-fibrosis-and-valvulopathy-comparison-to-known-cardiotoxins
#25
REVIEW
Antonin Rouaud, Abigail E Calder, Gregor Hasler
Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly involves ingesting sub-threshold doses of lysergic acid diethylamide (LSD), psilocybin, or other psychedelic drugs 2-4 times a week for at least several weeks, but potentially months or years. Concerningly, both LSD and psilocybin share structural similarities with medications which raise the risk of cardiac fibrosis and valvulopathy when taken regularly, including methysergide, pergolide, and fenfluramine...
January 12, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38491857/psychiatric-risks-for-worsened-mental-health-after-psychedelic-use
#26
JOURNAL ARTICLE
Alessia Marrocu, Hannes Kettner, Brandon Weiss, Richard J Zeifman, David Erritzoe, Robin L Carhart-Harris
BACKGROUND: Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited by biases and small sample sizes. The current analytical approach was motivated by the question of whether rare but significant adverse effects have been under-sampled in psychedelic research studies...
March 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38344912/what-is-the-impact-of-antidepressant-side-effects-on-medication-adherence-among-adult-patients-diagnosed-with-depressive-disorder-a-systematic-review
#27
REVIEW
Eleni Niarchou, L H Roberts, Bernard D Naughton
BACKGROUND: Medication adherence is a prerequisite to achieving beneficial treatment outcomes. In major depressive disorder, many patients fail to complete medication regimens, raising concern for poor treatment outcomes. It is usual to experience adverse drug reactions (ADRs) while taking antidepressants, and relative discomfort is reported by patients. AIMS: The present review focuses on the presence of antidepressant-related side effects and the subsequent relationship with medication non-adherence...
February 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38240068/older-adults-in-psychedelic-assisted-therapy-trials-a-systematic-review
#28
REVIEW
Lisa Bouchet, Zachary Sager, Antoine Yrondi, Kabir B Nigam, Brian T Anderson, Stephen Ross, Petros D Petridis, Yvan Beaussant
BACKGROUND: Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential distress, and posttraumatic stress disorder. AIMS: The goal of this study was to quantify the prevalence of older adults enrolled in psychedelic clinical trials and explore safety data in this population...
January 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/37947321/the-psychedelic-effects-of-cannabis-a-review-of-the-literature
#29
REVIEW
David Wolinsky, Frederick Streeter Barrett, Ryan Vandrey
Cannabis and classic psychedelics are controlled substances with emerging evidence of efficacy in the treatment of a variety of psychiatric illnesses. Cannabis has largely not been regarded as having psychedelic effects in contemporary literature, despite many examples of historical use along with classic psychedelics to attain altered states of consciousness. Research into the "psychedelic" effects of cannabis, and delta-9-tetrahydrocannabinol (THC) in particular, could prove helpful for assessing potential therapeutic indications and elucidating the mechanism of action of both cannabis and classic psychedelics...
January 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38159102/neural-correlates-of-episodic-memory-decline-following-electroconvulsive-therapy-an-exploratory-functional-magnetic-resonance-imaging-study
#30
JOURNAL ARTICLE
Jeff Zarp Petersen, Julian Macoveanu, Alexander Tobias Ysbæk-Nielsen, Lars Vedel Kessing, Martin Balslev Jørgensen, Kamilla Woznica Miskowiak
BACKGROUND: Electroconvulsive therapy (ECT) is an efficient and rapid-acting treatment indicated for severe depressive disorders. While ECT is commonly accompanied by transient memory decline, the brain mechanisms underlying these side effects remain unclear. AIMS: In this exploratory functional magnetic resonance (fMRI) study, we aimed to compare effects of ECT versus pharmacological treatment on neural response during episodic memory encoding in patients with affective disorders...
December 30, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38151883/cilia-loss-on-distinct-neuron-populations-differentially-alters-cocaine-induced-locomotion-and-reward
#31
JOURNAL ARTICLE
Thomas Everett, Tyler W Ten Eyck, Chang-Hung Wu, Amanda L Shelowitz, Sofia M Stansbury, Alexandra Firek, Barry Setlow, Jeremy C McIntyre
BACKGROUND: Neuronal primary cilia are being recognized for their role in mediating signaling associated with a variety of neurobehaviors, including responses to drugs of abuse. They function as signaling hubs, enriched with a diverse array of G-protein coupled receptors (GPCRs), including several associated with motivation and drug-related behaviors. However, our understanding of how cilia regulate neuronal function and behavior is still limited. AIMS: The objective of the current study was to investigate the contributions of primary cilia on specific neuronal populations to behavioral responses to cocaine...
December 27, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38151862/arbitration-between-model-free-and-model-based-control-is-not-affected-by-transient-changes-in-tonic-serotonin-levels
#32
JOURNAL ARTICLE
Maximilian D Gilger, Lydia Hellrung, Philipp T Neukam, Nils B Kroemer, Stephan Nebe, Shakoor Pooseh, Yacila I Deza-Lougovski, Michael N Smolka
BACKGROUND: Serotonin has been suggested to modulate decision-making by influencing the arbitration between model-based and model-free control. Disruptions in these control mechanisms are involved in mental disorders such as drug dependence or obsessive-compulsive disorder. While previous reports indicate that lower brain serotonin levels reduce model-based control, it remains unknown whether increases in serotonergic availability might thus increase model-based control. Moreover, the mediating neural mechanisms have not been studied yet...
December 27, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38140891/longitudinal-associations-between-psychedelic-use-and-unusual-visual-experiences-in-the-united-states-and-the-united-kingdom
#33
JOURNAL ARTICLE
Otto Simonsson, Peter S Hendricks, Cecilia Ud Stenfors, Simon B Goldberg, Ludwig Honk, Walter Osika
BACKGROUND: Whereas findings from case reports and cross-sectional studies suggest that naturalistic psychedelic use may be associated with unusual visual experiences that occur after the acute pharmacological effects have subsided, such findings need to be replicated in longitudinal studies to better understand potential cause-and-effect relationships. AIMS: To investigate longitudinal associations between naturalistic psychedelic use and unusual visual experiences...
December 23, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38126253/dose-of-selective-serotonin-reuptake-inhibitors-and-risk-of-upper-gastrointestinal-bleeding-in-older-adults
#34
JOURNAL ARTICLE
Yu-Hsien Li, Liang-Wen Hang, Chih-Hsin Muo, Sheng-Jen Chen, Pei-Chun Chen
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) have been associated with an increased risk of upper gastrointestinal bleeding (UGIB) in older patients but little is known about the risk associated with individual SSRI drugs and doses. AIMS: To quantify the risk of UGIB in relation to individual SSRI use in older adults. METHODS: We conducted a nested case-control study within a cohort of 9565 patients aged ⩾65 years prescribed SSRIs from 2000 to 2013 using claims data of universal health insurance in Taiwan...
December 21, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38126222/clinical-benefits-and-bioequivalence-of-vortioxetine-oral-drop-solution-versus-oral-tablets
#35
JOURNAL ARTICLE
Andrea Fagiolini, Michael Adair, Kamilla Buchberg Petersen, Johan Areberg, Michael Cronquist Christensen
BACKGROUND: Vortioxetine is efficacious and well tolerated in patients with major depressive disorder (MDD) and is available as an immediate-release tablet and oral drop solution. The oral drop solution may offer clinical benefits versus a tablet, such as the reduced risk of nausea, personalised dosing and ease of administration. AIMS: To investigate the bioequivalence of vortioxetine 20 mg/mL oral drop solution versus a 20 mg immediate-release tablet...
December 21, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38069489/impaired-face-symmetry-detection-under-alcohol-but-no-beer-goggles-effect
#36
JOURNAL ARTICLE
Alistair J Harvey, Ciara White, Kathleen Madelin, Ed Morrison
BACKGROUND: The 'beer goggles' phenomenon describes sexual attraction to individuals when alcohol intoxicated whom we would not desire when sober. One possible explanation of the effect is that alcohol impairs the detection of facial asymmetry, thus lowering the drinker's threshold for physical attraction. AIMS: We therefore tested the hypotheses that higher breath alcohol drinkers would award more generous ratings of attractiveness to asymmetrical faces, and be poorer at discriminating bilateral facial asymmetry than less intoxicated counterparts...
December 8, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38069478/the-relation-between-naturalistic-use-of-psychedelics-and-perception-of-emotional-stimuli-an-event-related-potential-study-comparing-non-users-and-experienced-users-of-classic-psychedelics
#37
JOURNAL ARTICLE
Paweł Orłowski, Justyna Hobot, Anastasia Ruban, Jan Szczypiński, Michał Bola
BACKGROUND: Previous research has suggested that controlled administration of psychedelic substances can modulate emotional reactivity, enhancing positive and diminishing negative emotions. However, it is unclear whether similar effects are associated with using psychedelics in less-controlled naturalistic environments. AIMS: This cross-sectional study investigated the neural markers associated with the perception of emotional stimuli in individuals with extensive experience of naturalistic psychedelic use (15 or more lifetime experiences), comparing them to non-users...
December 8, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38050326/development-of-the-protective-strategies-for-psychedelics-scale-a-novel-inventory-to-assess-safety-strategies-in-the-context-of-psychedelics
#38
JOURNAL ARTICLE
Maha N Mian, Brianna R Altman, Fiona Low, Mitch Earleywine
BACKGROUND: Individuals who use psychedelics take efforts to mitigate unintended consequences. Despite the demonstrated utility of analogous protective behavioral strategies (PBS) assessments for other substances, no standardized scale exists to capture these protective strategies for psychedelic use. OBJECTIVE: The present study addresses a notable gap concerning the assessment of psychedelic use, specifically by developing a scale measuring the protective strategies employed around use, called the Protective Strategies for Psychedelics Scale (PSPS)...
December 4, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38059356/abuse-potential-assessment-of-the-dual-orexin-receptor-antagonist-daridorexant-in-rats
#39
JOURNAL ARTICLE
Michel A Steiner, Michael Toeroek-Schafroth, Maria Elena Giusepponi, Lisa Dacome, Michela Tessari
BACKGROUND: Drugs that act on the central nervous system (CNS) and have sedative effects can lead to abuse in humans. New CNS-active drugs often require evaluation of their abuse potential in dedicated animal models before marketing approval. Daridorexant is a new dual orexin receptor antagonist (DORA) with sleep-promoting properties in animals and humans. It was approved in 2022 in the United States and Europe for the treatment of insomnia disorder. AIMS: Nonclinical evaluation of abuse potential of daridorexant using three specific rat models assessing reinforcement, interoception, and withdrawal...
December 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/38009477/treating-posttraumatic-stress-disorder-and-alcohol-use-disorder-comorbidity-current-pharmacological-therapies-and-the-future-of-mdma-integrated-psychotherapy
#40
REVIEW
Brian J Gully, Erica Eaton, Christy Capone, Carolina L Haass-Koffler
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur in patients who have experienced trauma. This comorbidity leads to a vicious cycle where PTSD symptoms beget heavy drinking and vice versa. There are no FDA-approved medications to treat PTSD-AUD; therefore, individuals suffering from this comorbidity are treated with medication approved to treat the disorders separately or with off-label pharmacological interventions. However, these medications are limited in their efficacy for treating PTSD-AUD comorbidity...
November 27, 2023: Journal of Psychopharmacology
journal
journal
30126
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.